Molecular Weight: 396.51
Molecular Formula: C21H24N4O2S
Canonical SMILES: C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O
InChI: InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
InChIKey: PBAPPPCECJKMCM-IBGZPJMESA-N
Boiling Point: 690.0±55.0 °C at 760 mmHg
Melting Point: 138-145°C
Purity: 98%
Application: Adrenergic beta-3 Receptor Agonists
Storage: Store in a tightly closed container , in a cool and dry place.
Synonyms: YM-178; YM 178; YM178
DescriptionMirabegron (formerly YM-178, trade name Myrbetriq) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012. Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity
More details are to be found on
supplier website
